Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population.

The relationship between neurodegenerative conditions and late-life mood disorders (LLMDs) is largely unexplored.

MSD has begun the randomised MOBILIZE-1 Phase III trial to assess the investigational quadrivalent vaccine, V181.

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in ...

At the CTO West Coast conference, experts discussed the future of oncology clinical trials and key themes surrounding them.

At a panel at CTO West Coast, experts from biopharmaceutical companies outlined innovative strategies to shape the future of ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

Public and professional symptom recognition, accessibility to healthcare and diagnostics can be timely but also unreliable.